The FDA last week granted a priority review to...

...Pfizer and Merck KGaA's Bavencio for the treatment of bladder cancer in patients whose cases do not progress after induction chemo. The bladder cancer market is crowded, with drugs like Tecentriq and Keytruda holding stronger footholds on national formularies, so an additional indication could give Bavencio a much-needed edge. For the treatment of urothelial or bladder cancer, Bavencio currently holds preferred status for just 3% of covered lives, and is not covered for 21% of lives.

SOURCE: MMIT Analytics, as of 4/13/20